Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus ERYTHROMYCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus ERYTHROMYCIN STEARATE.
E.E.S. 200 vs ERYTHROMYCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
Erythromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptides.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
250-500 mg orally every 6 hours or 500-1000 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
1.4-2 hours in adults with normal renal function; prolonged to 5-6 hours in anuria; unchanged in hepatic impairment.
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Primarily excreted in bile as active drug; about 2-5% excreted renally as unchanged drug. Up to 15% excreted in feces.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic